# Biogen: Phase 1 study closed enrollment, 62 enrolled (Healthy Volunteer, Muscular Atrophy, Spinal)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Biogen |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec |
| NCT ID | NCT05575011 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Healthy Volunteer; Muscular Atrophy, Spinal |
| Intervention types | drug |
| Target enrollment | 62 |
| Site countries | Belgium, Canada, France, Germany, Italy, Netherlands, Poland, South Korea, United Kingdom |
| Posted | 2022-10-12 |
| Planned start | 2022-10-10 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-23 |
| Last update posted | 2026-10-23 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05575011). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.